Company Overview Biota Holdings is a Pharmaceutical company
engaged in anti- infective drug R&D, and its commercialization
to treat respiratory diseases, particulary Influenza. Biotas
blockbuster product, Relenza, 1 st in class NAI is marketed by GSK.
R&D activities focus on the development of drug candidates for
the treatment of : HCV infections RSV infections HRV infections The
company has several partnerships with Pharmaceuticals such as:
Slide 3
Company snapshot In 2010 Biota Holdings Ltd operates with 3
subsidiaries
Slide 4
Company snapshot Biotas Headquarters in Melbourne, Australia 34
Employees estimated Mr Peter Cook CEO Managing director Since 2005
Dr James Fox Chairman since 2009 Dr Simon Tucker Vice President
Research Since 1997 Dr Leigh Farrell Vice President Business D
Since 2006 Dr Jane Ryan Vice President Product D Since 1997 Dr John
Lambert Executive director Since 2002
Slide 5
Company snapshot Biota Holdings floated on the Australian Stock
Exchange ( ASX ) 2006 Biota admitted to the S&P/ASX 300 index
Biota datas: 174 m shares for a AUD $324 m Market Cap
Slide 6
Financial performance The Company reported: Financial year end
June Revenues of $60.56m during the fiscal year ended June 2009,
increase of 54.11% over 2008 Net Profit of $38.18m in 2009, whereas
Biota reported a net loss of 6.49m during 2008
Slide 7
Financial report Biota Holdings Limited Income Statements For
the year ended 30 June 2009 Others incomes : $22.776 m ( suit GSK )
Total Revenues : $83.334 m
Slide 8
Financial report Biota Holdings Limited Expenses Statements For
the year ended 30 June 2009
Slide 9
Financial report Biota Holdings Limited Income/Expenses
Statements For the year ended 30 June 2009
Slide 10
Financial report Biota Holdings Limited For the year ended 30
June 2009 Total Revenues : $83.334 m Total Expenses : $ 41.517 m
R&D : 42% Revenues Litigation : 12% Revenues Salaries : 7.10%
Revenues Sub-royalty : 7% Revenues Finance cost : 0.2%
Revenues
Slide 11
Biota Holdings Limited Balance sheets Strong cash position ~
$86.7million ~ 1.43 x Incomes ~ 1 year available Total equity ~ $97
million Financial report For the year ended 30 June 2009
Slide 12
Financial report Biota Holdings Limited Balance sheets Total
Assets ~ $111,629 million Total Liabilities Total equity ~ $ 97,032
+ Liabilities ~ $ 12,454 = ~ $111,629 million Assets =
Liabilities
Slide 13
Financial position Analysis Biota Holdings Limited vs
Pharmaceuticals & Healthcare sector (Oz) during the period
2005-2009 100.61 % Annual growth rate, 11.8% above the average
sector 3 kinds of ratios for the fiscal year year 2009:
Profitability ratios: 69.05 % operating margin OM, 18.5 % above the
average sector 39.4 % return on equity ROE, 16.1 % above the
average sector Operating costs ratios: 31 % operating costs (%
sales) OP over 5 years Liquidity ratios: 7,6 % current ratio CR
over 5 years
Slide 14
Profitability ratios To assess the Biotas ability to generate
earnings based on Revenues 69.05 % operating margin, 18.5 % above
the average sector OP used to mesure the Biotas Pricing strategy
& Operating efficiency OM = (Operating Income/ revenues) *
100
Slide 15
Profitability ratios To assess the Biotas ability to generate
earnings based on Ressources used 39.4 % return on equity, 16.1 %
above the average sector OP used to mesure the rate Of Return on
the Shareholders equity ROE = (Net Income/Shareholders Equity) *
100
Slide 16
Operating cost ratio Operating costs : To understand the costs
the company is incurring as % of sales 31 % operating costs (%
sales) OP in 2009 Operating cost = (operating expenses/Revenues) *
100 20052006200720082009 Op costs (% sales)
502,86181,5068,08123,6930,95
Slide 17
Liquidity ratios Current ratio ( absolute ratio ) Current ratio
2009 = 7,61 Used to determine the Biota ability to pay off its
short-terms debts obligations ( the highter the value ratio is, the
larger the margin of safety biota would possese to cover short term
debts) ( if ratio = 1 near Bankruptcy !! ) Current ratio= (Current
assets/Current liabilities) 20052006200720082009 Current ratio
6,294,935,273,337,61
Slide 18
Stocks Analysis S&P /ASX 300, in the Intersuisse
Biotechnologies Index Market capitalisation ~ $324m Shareholders ~
13,300 Total shares ~ 174m
Slide 19
Stocks Analysis Bird Flu Rumour 11 Aug 2005 Inside Traders wave
+ 30,6% Mediatization + 312,65% 10/10/2005 Nov 2005 French order 9m
courses April 2006 US defense order 5,5m courses Jul 2006 US order
16m courses First Profitability announced Swine Flu Rumour 24 April
2009 Inside Traders wave + 31,34% Mediatization + 296,32%
27/04/2009 Open gap 24/10/2009 Nasdaq biotech
Slide 20
PER Capital market ratio: Mesure of the price paid for a share
relative to the annual income earned per share. PER (Price earning
ratio) = 9,66 ; vs 11,4 Aussie sector average Capital management :
$20m return to shareholders in Dec 2009 ! 1st time since 1985 ~0,12
cents per share dividend ~ significant Stocks Analysis
Slide 21
SWOT Analysis StrengthsWeaknesses Strong In-house Research
capabilities Flagship Product: Relenza Strong Financial Position
Business Concentration: Aussie Limited Investor Confidence
OpportunitiesThreats Significant Collaborations Market Potential:
HCV Emerging Markets Competitive Pressures Government Regulations
Uncertain R&D Outcomes
Slide 22
THE END References: - Annual report 2009 - Global market
directs - Business week - Intersuisse - Euronext - Google fiinance
- biota website